

## Agreement with Australia's leading Men's Health Pharmacy for access to SPONTAN®

19 December 2024

### Highlights:

- Key access agreement with Men's Health Downunder, Australia's largest men's health pharmacy clinic network
- Agreement enables SPONTAN® availability through an established pharmacy network under the Therapeutic Goods Administration's (TGA) Special Access Scheme
- Provides access to Men's Health Downunder's significant referral network of GPs, urologists, and sexual health clinics
- First patient has received SPONTAN® through MHDU's pharmacy network

LTR Pharma Limited (ASX:LTP) ("LTR Pharma", "the Company") is pleased to announce it has entered into an access agreement with [Men's Health Downunder](#) ("MHDU") to facilitate the supply of SPONTAN® through the Therapeutic Goods Administration's (TGA) Special Access Scheme (SAS).

MHDU is a specialised men's health provider. It operates a multidisciplinary network of pharmacists, GPs, nurses, and allied health professionals across multiple locations, specialising in comprehensive urological healthcare solutions.

The agreement leverages MHDU's established network of specially trained pharmacists and comprehensive men's health services across multiple locations in Australia. MHDU's clinics currently service over 1,000 patients annually through specialist urological health support services.

The agreement provides LTR Pharma access to MHDU's extensive referral network, which includes general practitioners, urologists, and sexual health clinics. This partnership aligns with the Company's strategy to introduce SPONTAN through trusted healthcare providers while gathering valuable real-world patient data.

**MHDU Founder and Executive Chairman, Brad Butt said:** *"This collaboration with LTR Pharma enhances our ability to provide innovative solutions for men's health concerns. SPONTAN's rapid-onset profile addresses a significant unmet need in erectile dysfunction treatment, complementing our multi-disciplinary and multi-modal approach to men's healthcare."*

### Commercial Development and Market Preparation

The agreement builds upon LTR Pharma's recent achievements in establishing early access to SPONTAN through the TGA's Special Access Scheme and Authorised Prescriber Scheme. MHDU's established presence in key Australian markets and its comprehensive consultation approach align with the Company's commitment to improving patient outcomes in men's health.

The Company and MHDU are collaborating on initial packaging solutions designed for pharmacy availability. This development work represents an important step in preparing SPONTAN for broader market access, anticipated in early 2025. While SPONTAN is currently available through the TGA's early access scheme, the packaging requirements for these schemes differ from what will be used for full commercial launch following TGA approval.

The partnership with MHDU provides valuable insights into pharmacy and patient needs, which will inform the development of commercial packaging ahead of full market launch.

**LTR Pharma Chairman, Lee Rodne said:** *"The agreement with Men's Health Downunder represents another significant milestone in SPONTAN's commercialisation journey. By partnering with Australia's largest men's health pharmacy clinic, we continue to broaden access to SPONTAN while maintaining our commitment to patient care through qualified healthcare professionals."*

**-Ends-**

This announcement has been approved by the Board of Directors.

#### **About LTR Pharma**

LTR Pharma is focused on improving men's health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma's lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

#### **For further information please contact:**

Media enquiries  
Haley Chartres  
[haley@hck.digital](mailto:haley@hck.digital)

Investor enquiries  
Peter McLennan  
[investors@ltrpharma.com](mailto:investors@ltrpharma.com)